Risk factors
Protagonist Therapeutics (PTGX) risk factors
Item 1A of every Protagonist Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks6 new1 dropped17 reworded
New risks broaden exposure to strategic transactions, FDA disruption, shareholder activism, trade-secret loss, and tax-law changes.
Filed Feb 25, 2026 - FY2024 10-K risk factors48 risks
Clinical success depends heavily on lead candidates rusfertide for polycythemia vera and JNJ-partnered icotrokinra. Operations rely completely on third-party contract manufacturers for drug supplies. Substantial accumulated deficit of 340.5 million dollars requires ongoing external funding.
Filed Feb 21, 2025